COVID-19: Collaborative research with Peptidream, Merck & Co., Inc.: Development of new therapeutic drug for corona
[Tokyo 12th Reuters]-
Peptide Dream (4587.T):
On June 12, it announced that it will conduct research and development of a novel coronavirus infection treatment drug in collaboration with US pharmaceutical giant Merck & Co. (MRK.N).
Peptide therapeutics:
Peptide therapeutics to be jointly researched and developed
In addition to the current new coronavirus,
For all mutant coronaviruses that may occur in the future
Effectiveness can be expected.
What is Peptide Dream:
A bio-venture company from the University of Tokyo aimed at discovering and developing non-standard peptide therapeutics.
https://www.google.co.jp/amp/s/jp.mobile.reuters.com/article/amp/idJPKBN23J0HR
PeptiDream Announces Collaboration with Merck & Co., Inc.,
Kenilworth, N.J., U.S.A. to Develop Candidate COVID-19 Therapies
KANAGAWA, JAPAN – June 12th, 2020 – PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)
today announced that it has entered into a collaboration with Merck & Co. Inc., Kenilworth NJ, USA, (“Merck”), known as MSD outside the United States and Canada, for the discovery and development of novel peptide therapeutics capable of neutralizing both the current SARS-CoV-2 virus (Coronavirus Disease “COVID19”) and potential future Coronavirus (“CoV”) outbreaks.
Under this collaboration, the companies will focus their combined efforts on developing peptide therapeutics that may be effective against multiple coronavirus strains.
The agreement builds on the original research collaboration and license agreement between both companies announced April 29, 2015.
PeptiDream will receive an undisclosed upfront payment, as well as be eligible for payments associated with the achievement of certain preclinical, clinical, as well as royalties on future sales of any products that arise from the collaboration.
“We are excited to announce this partnership focused on the discovery and development of peptide candidates targeting multiple coronaviruses. Our wide-ranging collaboration continues to make exceptional progress and I am confident that together we can make an impact in combatting this global challenge,” said Patrick C. Reid PhD, President & CEO of PeptiDream.
“Our experience has shown that good science and strong collaborations are essential to develop medicines and vaccines, and that is especially true now in a global public health emergency,” said Emma Parmee DPhil, vice president, Discovery Chemistry research,Merck & Co., Inc., Kenilworth, NJ, USA., “We look forward to working with scientists at PeptiDream to identify candidates targeting SARS CoV-2 and other coronaviruses.”
PeptiDream is pursuing a multi-pronged strategy toward identifying peptide candidates targeting different sites/regions of coronaviruses as announced previously on April 30, 2020